-
Mashup Score: 1Highlights from the immunotherapy in CLL session - 2 year(s) ago
David Maloney, MD, PhD, Fred Hutchinson Cancer Research Center, Seattle, WA, shares the highlights from the immunotherapy session at iwCLL…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 8The effect of COVID-19 on CLL patient experiences - 2 year(s) ago
Zack Pemberton-Whiteley, Leukemia Care, Worcester, UK, discusses the findings of a study investigating the experiences of patients with chronic lymphocytic…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Prognostic markers for the treatment of CLL - 2 year(s) ago
Lydia Scarfò, MD, Vita-Salute San Raffaele University & IRCCS San Raffaele Scientific Institute, Milan, Italy, discusses the challenges of selecting…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0BCL receptor signalling and CLL cell migration - 2 year(s) ago
Dimitar Efremov, MD, PhD, International Centre for Genetic Engineering and Biotechnology, Trieste, Italy, discusses the role of different receptor-ligand systems…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Relevance of current prognostication and prediction markers for CLL with new targeted therapies - 2 year(s) ago
Richard Rosenquist, MD, PhD, Karolinska Institute, Sweden, Stockholm, discusses current genetic markers used for the prediction and prognostication of chronic…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0RESONATE-2: ibrutinib and chlorambucil for frontline CLL - 2 year(s) ago
Tadeusz Robak, MD, PhD, of the Medical University of Lodz, Lodz, Poland, provides us with an update on the RESONATE-2…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1Addressing autoimmune cytopenia in CLL - 2 year(s) ago
Kerry Rogers, MD, The Ohio State University, Columbus, OH, discusses the management of autoimmune cytopenia in patients with chronic lymphocytic…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Frontline Ibrutinib Shows Sustained Survival Advantage Over Chlorambucil in CLL at 7 Years - 2 year(s) ago
Tadeusz Robak, MD, discussed the 7-year safety and efficacy data from the RESONATE-2 trial examining frontline ibrutinib in CLL.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1Frontline Ibrutinib Shows Sustained Survival Advantage Over Chlorambucil in CLL at 7 Years - 2 year(s) ago
Tadeusz Robak, MD, discussed the 7-year safety and efficacy data from the RESONATE-2 trial examining frontline ibrutinib in CLL.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1Prediction and prognostication methods for CLL - 2 year(s) ago
Arnon Kater, MD, PhD, University of Amsterdam, Amsterdam, Netherlands, shares his views on current prediction and prognostication methods for the…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
David Maloney of @fredhutch discusses pros and cons of allo-SCT and CAR-T therapies for chronic lymphocytic #Leukemia. ➡️Watch here: https://t.co/Smssm5lNAH @iwCLL #iwCLL2021 #CLLsm #LEUsm #ImmunoOnc #CART #BMTsm #HemOnc